Iain Squire
A5075319533- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Fibrosis and Remodeling
- Cardiac pacing and defibrillation studies
- Potassium and Related Disorders
- Cardiovascular Disease and Adiposity
- Cardiac electrophysiology and arrhythmias
- Coronary Interventions and Diagnostics
- Cardiac Valve Diseases and Treatments
- Protease and Inhibitor Mechanisms
- Diabetes Treatment and Management
- Signaling Pathways in Disease
- Cardiac, Anesthesia and Surgical Outcomes
- Peptidase Inhibition and Analysis
- Erythropoietin and Anemia Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Advanced MRI Techniques and Applications
- Iron Metabolism and Disorders
- Cardiac Arrest and Resuscitation
- Frailty in Older Adults
- Cardiac Health and Mental Health
- Cardiac Structural Anomalies and Repair
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
National Institute for Health Research
2016-2025
University of Leicester
2016-2025
Glenfield Hospital
2016-2025
University Hospitals of Leicester NHS Trust
2006-2025
NIHR Leicester Biomedical Research Centre
2017-2025
NIHR Leicester Cardiovascular Biomedical Research Unit
2015-2024
Karolinska Institutet
2023
NIHR Biomedical Research Centre at The Royal Marsden and the ICR
2019-2021
Boehringer Ingelheim (United States)
2021
Charité - Universitätsmedizin Berlin
2021
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless presence or absence diabetes. More evidence is needed regarding effects these drugs across broad spectrum failure, including those with a markedly reduced ejection fraction.
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with and a reduced ejection fraction, but their effects preserved fraction are uncertain.
Background— Clinical trials in heart failure have focused on the improvement symptoms or decreases risk of death and other cardiovascular events. Little is known about effect drugs clinical deterioration surviving patients. Methods Results— We compared angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with angiotensin-converting enzyme enalapril (20 8399 patients reduced ejection fraction a double-blind trial. The analyses prespecified measures nonfatal deterioration. In comparison...
The role of the vasopressin system after acute myocardial infarction is unclear. Copeptin, C-terminal part prohormone, secreted stoichiometrically with vasopressin. We compared prognostic value copeptin and an established marker, N-terminal pro-B-type natriuretic peptide (NTproBNP), infarction.In this prospective single-hospital study, we recruited 980 consecutive post-acute patients (718 men, median [range] age 66 [24 to 95] years), follow-up over 342 (range 0 764) days. Plasma was highest...
Background— The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure reduced ejection fraction are not known. We investigated these the Prospective Comparison ARNI With ACEI to Determine Impact on Global Mortality Morbidity Heart Failure (PARADIGM-HF) trial. Methods Results— examined clinical outcomes 8399 according history diabetes glycemic status (baseline hemoglobin A1c [HbA1c]: <6.0% [<42 mmol/mol], 6.0%–6.4% [42–47 mmol/mol; mellitus], ≥6.5% [≥48...
Serelaxin is a recombinant form of human relaxin-2, vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy. Previous studies have suggested treatment with serelaxin may result in relief symptoms better outcomes patients acute heart failure.In this multicenter, double-blind, placebo-controlled, event-driven trial, we enrolled who were hospitalized for failure had dyspnea, vascular congestion on chest radiography, increased plasma concentrations...
Nonadherence to antihypertensive treatment is a critical contributor suboptimal blood pressure control. There are limited and heterogeneous data on the risk factors for nonadherence because few studies used objective-direct diagnostic methods. We high-performance liquid chromatography-tandem mass spectrometry of urine serum detect explored its association with main demographic- therapy-related in 1348 patients hypertension from 2 European countries. The rates were 41.6% 31.5% UK Czech...
Background: There are multiple risk factors for heart failure, but contemporary temporal trends according to sex, socioeconomic status, and ethnicity unknown. Methods: Using a national UK general practice database linked hospitalizations (1998–2017), 108 638 incident failure patients were identified. Differences in among patient groups adjusted sociodemographic age-adjusted investigated using logistic linear regression. Results: Over time, 5.3 year (95% CI, 5.2–5.5) age difference between...
Abstract Background and Aims What is the relationship between blood tests for iron deficiency, including anaemia, response to intravenous in patients with heart failure? Methods In IRONMAN trial, 1137 failure, ejection fraction ≤ 45%, either serum ferritin &lt; 100 µg/L or transferrin saturation (TSAT) 20% were randomized ferric derisomaltose (FDI) usual care. Relationships investigated baseline anaemia severity, TSAT, changes haemoglobin from 4 months, Minnesota Living Heart Failure...
Elevated concentrations of the acute-phase reactant C-reactive protein (CRP) predict ischemic cardiac events in both hospital- and population-based studies may signify a role for inflammation destabilization cardiovascular disease. We examined relationship between CRP outcome after acute stroke.This was subgroup analysis from prospective observational study based University Hospital Acute Stroke Unit serving population approximately 260 000. Survival time cause death up to 4 years index...
Abstract Relative survival is frequently used in population‐based studies as a method for estimating disease‐related mortality without the need information on cause of death. We propose an extension to relative flexible parametric model proposed by Royston and Parmar censored data. The provides smooth estimates excess rates using restricted cubic splines log cumulative hazard scale. approach has several advantages over some more standard models, which adopt piecewise approach, main being...
The aim of the present study was to compare prognostic value a novel and promising marker, copeptin, with B-type natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), on death or composite cardiovascular endpoint in patients who developed heart failure after an acute myocardial infarction (AMI). From subset 224 OPTIMAAL study, blood samples were drawn at mean 3 days AMI when all had signs and/or symptoms left ventricular ejection fraction <0.35. Endpoints interest mortality (primary...
Background— Prior studies in heart failure (HF) have used the Modification of Diet Renal Disease (MDRD) equation to calculate estimated glomerular filtration rate (eGFR). The Chronic Kidney Disease-Epidemiology Collaboration Group (CKD-EPI) provides a more-accurate eGFR than MDRD when compared against radionuclide gold standard. prevalence and prognostic import renal dysfunction HF if CKD-EPI is rather uncertain. Methods Results— We individual patient data from 25 prospective stratify...
To describe temporal profiles of plasma matrix metalloproteinases (MMP-2 and MMP-9), their relationship with echocardiographic (Echo) parameters left ventricular (LV) function remodelling, after acute myocardial infarction (AMI) in man.Plasma MMP-2 MMP-9 were assayed at intervals (0-12, 12-24, 24-48, 48-72, 72-96, > 96 h) 91 patients AMI (ST-elevation/non-ST-elevation 77/24; 73% male; 40% anterior site) on a single occasion 172 age- sex-matched control subjects stable coronary artery...